Heat Biologics Inc (HTBX)-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8013953)
◆英語タイトル:Heat Biologics Inc (HTBX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013953
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:60
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Heat Biologics Inc (Heat Biologics) is an immuno-oncology company that develops novel therapies to activate patient’s immune system against cancer. The company develops immune pan-antigen cytotoxic therapy, which is a therapeutic vaccine used in the treatment of cancer and infectious diseases. Its pipeline products include HS-110, which is used to treat non-small cell lung cancer, and HS-410 that is used in the treatment of non-muscle invasive bladder cancer. Heat Biologics conducts multiple clinical trials in various indications. The company’s product serves various therapeutic areas such as non-small cell lung cancer, HIV infection, parasitic infections, and others. It partners with other pharma companies for its research and development activities. Heat Biologics is headquartered in Durham, North Carolina, the US.

Heat Biologics Inc (HTBX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Heat Biologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Heat Biologics Inc, Medical Devices Deals, 2011 to YTD 2017 10
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Heat Biologics Raises USD0.5 Million in Venture Funding 12
Heat Biologics Raises US$5 Million In Venture Financing 13
Heat Biologics Raises US$2.83 Million In Venture Financing 14
Partnerships 15
Selexis and Pelican Therapeutics Enter into Agreement 15
Heat Biologics Enters into Agreement with Adaptive Biotechnologies 16
Licensing Agreements 17
University of Miami Enters into Licensing Agreement with Heat Biologics 17
Shattuck Labs Enters into Licensing Agreement with Heat Biologics 18
Heat Biologics Enters into Licensing Agreement with Columbia University 19
Heat Biologics Enters into Licensing Agreement for Multiple Myeloma Cell Line 20
Heat Biologics Enters into Licensing Agreement with University of Miami 21
Heat Biologics Amends License Agreement with University of Michigan 22
Heat Biologics Enters into Licensing Agreement with American Type Culture Collection 23
Heat Biologics Enters into Four Licensing Agreements with University of Miami 24
Equity Offering 26
Heat Biologics Prices USD2.5 Million of Public Offering of Shares 26
Heat Biologics Plans to Raise up to USD50 Million in Public Offering of Securities 27
Heat Biologics Prices Rights Offering of Shares for up to USD7.4 Million 28
Heat Biologics Raises USD4 Million in Public Offering of Common Stock 29
Heat Biologics Raises USD7 Million in Public Offering of Shares 30
Heat Biologics Raises USD12.3 Million in Public Offering of Shares 32
Heat Biologics Completes Underwriters’ Partial Exercise Of Over-Allotment Option For IPO Of Shares For US$27 Million 34
Acquisition 36
Heat Biologics Acquires 80% Stake in Pelican Therapeutics 36
Heat Biologics Inc – Key Competitors 37
Heat Biologics Inc – Key Employees 38
Heat Biologics Inc – Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Recent Developments 40
Financial Announcements 40
Nov 13, 2017: Heat Biologics Reports Third-quarter 2017 Results and Corporate Update 40
May 11, 2017: Heat Biologics Provides Business and Clinical Update for the First Quarter of 2017 41
Mar 31, 2017: Heat Biologics Reports Fiscal Year 2016 Financial Results 43
Nov 10, 2016: Heat Biologics Provides Corporate Update and Reports Third Quarter 2016 Financial Results 45
Aug 15, 2016: Heat Biologics Provides Corporate Update and Reports Second Quarter 2016 Financial Results 47
May 11, 2016: Heat Biologics Reports First Quarter 2016 Financial Results 49
Feb 18, 2016: Heat Biologics Reports Fiscal Year 2015 Financial Results 50
Corporate Communications 51
Oct 23, 2017: Heat Biologics and its Pelican Therapeutics Subsidiary Appoint Two New Members to their Scientific Advisory Boards 51
Jul 03, 2017: Dr. Jeff Hutchins Appointed Chief Operating Officer for Heat Biologics 52
Jan 04, 2017: Heat Biologics Appoints Jeff Hutchins, Ph.D., as Chief Scientific Officer 53
Apr 25, 2016: Heat Biologics Appoints Dr. John Prendergast to Board of Directors 54
Product News 55
Jul 07, 2016: Heat Biologics Announces “Cancer Immunology Research” Publication Featuring its ComPACT Platform Technology 55
06/28/2017: Pelican Therapeutics, a Subsidiary of Heat Biologics, Receives First Tranche of $15.2 Million CPRIT Grant Award 56
05/19/2016: Pelican Therapeutics awarded $15.2 million to develop novel immune therapy for multiple cancers 57
03/16/2017: Florida Department of Health Awards Three-Year Grant to Develop gp96-based Zika Vaccine 58
Clinical Trials 59
Mar 07, 2016: Heat Biologics Presents Positive ComPACT Preclinical Data at the Keystone Symposia 59
Appendix 60
Methodology 60
About GlobalData 60
Contact Us 60
Disclaimer 60

List of Tables
Heat Biologics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Heat Biologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Heat Biologics Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Heat Biologics Inc, Medical Devices Deals, 2011 to YTD 2017 10
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Heat Biologics Raises USD0.5 Million in Venture Funding 12
Heat Biologics Raises US$5 Million In Venture Financing 13
Heat Biologics Raises US$2.83 Million In Venture Financing 14
Selexis and Pelican Therapeutics Enter into Agreement 15
Heat Biologics Enters into Agreement with Adaptive Biotechnologies 16
University of Miami Enters into Licensing Agreement with Heat Biologics 17
Shattuck Labs Enters into Licensing Agreement with Heat Biologics 18
Heat Biologics Enters into Licensing Agreement with Columbia University 19
Heat Biologics Enters into Licensing Agreement for Multiple Myeloma Cell Line 20
Heat Biologics Enters into Licensing Agreement with University of Miami 21
Heat Biologics Amends License Agreement with University of Michigan 22
Heat Biologics Enters into Licensing Agreement with American Type Culture Collection 23
Heat Biologics Enters into Four Licensing Agreements with University of Miami 24
Heat Biologics Prices USD2.5 Million of Public Offering of Shares 26
Heat Biologics Plans to Raise up to USD50 Million in Public Offering of Securities 27
Heat Biologics Prices Rights Offering of Shares for up to USD7.4 Million 28
Heat Biologics Raises USD4 Million in Public Offering of Common Stock 29
Heat Biologics Raises USD7 Million in Public Offering of Shares 30
Heat Biologics Raises USD12.3 Million in Public Offering of Shares 32
Heat Biologics Completes Underwriters’ Partial Exercise Of Over-Allotment Option For IPO Of Shares For US$27 Million 34
Heat Biologics Acquires 80% Stake in Pelican Therapeutics 36
Heat Biologics Inc, Key Competitors 37
Heat Biologics Inc, Key Employees 38
Heat Biologics Inc, Subsidiaries 39

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Heat Biologics Inc (HTBX)-製薬・医療分野:企業M&A・提携分析(Heat Biologics Inc (HTBX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆